Radioactive beads offer new hope for inoperable liver cancer
NCT ID NCT04736121
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a treatment called selective internal radiation therapy (SIRT) for people with liver cancer that cannot be removed by surgery. Tiny radioactive beads are injected into the liver to deliver radiation directly to tumors. The goal is to shrink the cancer and control the disease. About 100 adults with early to intermediate stage liver cancer will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BCLC STAGE A HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Allegheny-Singer Research Institute
Pittsburgh, Pennsylvania, 15212, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Clinical Research Institute and Methodist Hospital
Dallas, Texas, 75203, United States
-
Columbia University CUIMC/NYPH
New York, New York, 10032, United States
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Hospital of the University Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Inland Imaging
Spokane, Washington, 99208, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Miami Cardiac and Vascular Institute at Baptist Hospital
Miami, Florida, 33176, United States
-
Providence St. Joseph Hospital
Orange, California, 92868, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
Sarasota Memorial Health Care System
Sarasota, Florida, 34239, United States
-
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
The University of Vermont Medical Center
Burlington, Vermont, 05401, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Irvine
Orange, California, 92868, United States
-
University of California Los Angeles - Ronald Reagan Medical Center
Los Angeles, California, 90095, United States
-
University of Cincinnati Cancer Center CTO
Cincinnati, Ohio, 45267, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of North Carolina - Chapel Hill Medical Center
Chapel Hill, North Carolina, 27599, United States
-
University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
-
Wake Forest Baptist Health
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- AI takes on liver cancer: could a computer help pick the right immunotherapy?
- Immunotherapy combo tested against untreatable liver cancer
- Liver cancer drug combo shows promise in large trial
- New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo
- New radioactive beads aim to outperform standard liver cancer therapy